A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

NCT07189065 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG: Rocbrutinib
DRUG: Bendamustine
DRUG: Rituximab
DRUG: Lenalidomide

Sponsor

Guangzhou Lupeng Pharmaceutical Company LTD.